Neuralstem Archives | Be Korea-savvy
Neuralstem Provides Business Update and Reports Second Quarter 2018 Fiscal Results

Neuralstem Provides Business Update and Reports Second Quarter 2018 Fiscal Results

GERMANTOWN, Md., Aug. 15 (Korea Bizwire) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell and small molecule compound technologies, provides a business update and reported its financial results for the second quarter ended June 30, 2018.  “We are pleased to report a [...]

Neuralstem Announces NSI-189 Granted Orphan Drug Designation from the U.S. FDA for the Treatment of Angelman Syndrome

Neuralstem Announces NSI-189 Granted Orphan Drug Designation from the U.S. FDA for the Treatment of Angelman Syndrome

GERMANTOWN, Md., Aug. 9 (Korea Bizwire) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell technology, today announced that the U.S. Food and Drug Administration has granted orphan drug designation to NSI-189 for the treatment of Angelman syndrome. “Angelman Syndrome is a rare disease [...]

Neuralstem Appoints Jim Scully as Interim Chief Executive Officer

Neuralstem Appoints Jim Scully as Interim Chief Executive Officer

GERMANTOWN, Md., Aug. 6 (Korea Bizwire) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell and small molecule compound technologies, today announced that the Board of Directors has appointed Jim Scully as interim chief executive officer. Mr. Scully will assume the role effective [...]

CORRECTING and REPLACING – Neuralstem Announces Initiation of Phase 2 Clinical Trial of NSI-566 in Ischemic Stroke

CORRECTING and REPLACING – Neuralstem Announces Initiation of Phase 2 Clinical Trial of NSI-566 in Ischemic Stroke

GERMANTOWN, Md., Aug. 1 (Korea Bizwire) — In a release issued yesterday by Neuralstem, Inc. (Nasdaq:CUR), please note the headline should be, “Neuralstem Announces Initiation of Phase 2 Clinical Trial of NSI-566 in Ischemic Stroke,” rather than, “Neuralstem Announces Initiation of Phase 2 Clinical Trial of NSI-189 in Ischemic Stroke,” as originally issued. The corrected release [...]

Neuralstem Announces Presentation of Preclinical Data Demonstrating Neurogenic Compound NSI-189 Improves Cognition and Anxiety in a Mouse Model of Alzheimer’s Disease

Neuralstem Announces Presentation of Preclinical Data Demonstrating Neurogenic Compound NSI-189 Improves Cognition and Anxiety in a Mouse Model of Alzheimer’s Disease

GERMANTOWN, Md., Jul. 23 (Korea Bizwire) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced the presentation of data at the Alzheimer’s Association International Conference in Chicago, Illinois, demonstrating that oral administration of NSI-189 in a mouse model of Alzheimer’s Disease leads to a significant amelioration and/or improvement [...]

Neuralstem Awarded Phase I SBIR Contract to Support Research into Neural Stem Cell Therapy for Severe Traumatic Brain Injury

Neuralstem Awarded Phase I SBIR Contract to Support Research into Neural Stem Cell Therapy for Severe Traumatic Brain Injury

GERMANTOWN, Md., Jun. 11 (Korea Bizwire) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced that it has been awarded a Phase I Small Business Innovation Research (SBIR) contract by the Department of Defense (DoD). The award of $150,000 will support the Company’s ongoing efforts to develop its [...]

Neuralstem’s NSI-566 Stem Cell Therapy Confers Neurological Improvement in Spinal Cord Injury Patients with Complete Paraplegia

Neuralstem’s NSI-566 Stem Cell Therapy Confers Neurological Improvement in Spinal Cord Injury Patients with Complete Paraplegia

GERMANTOWN, Md., Jun. 4 (Korea Bizwire) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced the results from a study published in the journal Cell Stem Cell that support the potential of transplanted NSI-566, a human spinal cord-derived neural stem cell line (HSSC) to benefit patients with chronic [...]

Neuralstem to Participate at the BIO 2018 International Convention

Neuralstem to Participate at the BIO 2018 International Convention

GERMANTOWN, Md., May 29 (Korea Bizwire) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced that Karl Johe, PhD, Chief Scientific Officer of Neuralstem, will be providing a Company overview during the 2018 BIO International Convention in Boston, Massachusetts, on Monday, June 4, 2018 at 3:30pm ET.  A [...]

Neuralstem Provides Business Update and Reports First Quarter 2018 Fiscal Results

Neuralstem Provides Business Update and Reports First Quarter 2018 Fiscal Results

GERMANTOWN, Md., May 15 (Korea Bizwire) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell technology, provides a business update and reported its financial results for the first quarter ended March 31, 2018 . “We remain committed to the development of NSI-566, our [...]

Neuralstem Announces Publication of Long-Term Follow-up Data on ALS in the Annals of Clinical and Translational Neurology

Neuralstem Announces Publication of Long-Term Follow-up Data on ALS in the Annals of Clinical and Translational Neurology

GERMANTOWN, Md., May 3 (Korea Bizwire) —  Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced the results from a study published in the Annals of Clinical and Translational Neurology that support the potential of transplanted human spinal cord-derived neural stem cells (HSSC) to stabilize functioning of amyotrophic lateral [...]